BR112022004519A2 - Composições que compreendem citisina no tratamento e/ou prevenção de vício em sujeitos em necessidade do mesmo - Google Patents

Composições que compreendem citisina no tratamento e/ou prevenção de vício em sujeitos em necessidade do mesmo

Info

Publication number
BR112022004519A2
BR112022004519A2 BR112022004519A BR112022004519A BR112022004519A2 BR 112022004519 A2 BR112022004519 A2 BR 112022004519A2 BR 112022004519 A BR112022004519 A BR 112022004519A BR 112022004519 A BR112022004519 A BR 112022004519A BR 112022004519 A2 BR112022004519 A2 BR 112022004519A2
Authority
BR
Brazil
Prior art keywords
addiction
cytisine
treatment
subjects
prevention
Prior art date
Application number
BR112022004519A
Other languages
English (en)
Portuguese (pt)
Inventor
Anthony Clarke
A Jacobs Cindy
F Cain Daniel
Original Assignee
Achieve Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achieve Life Sciences Inc filed Critical Achieve Life Sciences Inc
Publication of BR112022004519A2 publication Critical patent/BR112022004519A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022004519A 2019-09-12 2020-08-14 Composições que compreendem citisina no tratamento e/ou prevenção de vício em sujeitos em necessidade do mesmo BR112022004519A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US202062988890P 2020-03-12 2020-03-12
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Publications (1)

Publication Number Publication Date
BR112022004519A2 true BR112022004519A2 (pt) 2022-05-31

Family

ID=74866435

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004519A BR112022004519A2 (pt) 2019-09-12 2020-08-14 Composições que compreendem citisina no tratamento e/ou prevenção de vício em sujeitos em necessidade do mesmo

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119587493A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof
EP4399517A4 (en) * 2021-09-08 2025-10-15 Achieve Life Sciences Inc ANALYTICAL METHODS FOR EVALUATING THE PURITY OF CYTISINE
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
WO2024226736A2 (en) * 2023-04-26 2024-10-31 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125699B (en) 1982-02-22 1986-02-12 Bruss Ni Sanitarno Gigieniches Medicinal preparation having antinicotine effect and method for obtention thereof
WO1998018798A1 (en) * 1996-10-30 1998-05-07 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN104906669A (zh) * 2007-03-30 2015-09-16 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
WO2014205449A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
JP6324964B2 (ja) 2013-08-23 2018-05-16 久光製薬株式会社 貼付剤
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
EP3658561A1 (en) * 2017-07-24 2020-06-03 Achieve Pharma UK Limited Cytisine salts
CA3153405A1 (en) * 2019-09-12 2021-03-18 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Also Published As

Publication number Publication date
EP4027815A4 (en) 2023-06-07
AU2020346695A1 (en) 2022-04-28
WO2021050203A1 (en) 2021-03-18
KR20220074895A (ko) 2022-06-03
JP2022548876A (ja) 2022-11-22
EP4027815A1 (en) 2022-07-20
CN114727647A (zh) 2022-07-08
US20210330652A1 (en) 2021-10-28
CN118286217A (zh) 2024-07-05
US20210077475A1 (en) 2021-03-18
EP4027815B1 (en) 2026-04-15
CN119564619A (zh) 2025-03-07
US20210077473A1 (en) 2021-03-18
CN119587493A (zh) 2025-03-11
MX2022002882A (es) 2022-05-10
US11083715B2 (en) 2021-08-10
JP7742832B2 (ja) 2025-09-22
CA3153405A1 (en) 2021-03-18
ZA202204075B (en) 2023-11-29
JP2025081331A (ja) 2025-05-27
US11083716B2 (en) 2021-08-10

Similar Documents

Publication Publication Date Title
BR112022004519A2 (pt) Composições que compreendem citisina no tratamento e/ou prevenção de vício em sujeitos em necessidade do mesmo
MX2025002382A (es) Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer
BR112015023203A2 (pt) métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
PH12017502103A1 (en) Methods and kits for treating depression
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
BRPI1013990A2 (pt) método para tratar uma doença , e, combinação anticâncer
BR112017008284A2 (pt) bifidobactérias ativadas e métodos para uso das mesmas
MX391720B (es) Terapia combinada para tratar cáncer.
WO2016025635A3 (en) Combination therapy for treating cancer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112018002941A2 (pt) métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
WO2016043874A3 (en) Combination therapy for treating cancer
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112018074152A8 (pt) Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
MX2019004766A (es) Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma.
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
CL2018003214A1 (es) Composiciones cosméticas prebióticas y uso de las composiciones cosméticas prebióticas
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112018068628A2 (pt) método de prevenção de doença do enxerto contra hospedeiro
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112016030064A2 (pt) ?métodos de tratamento de câncer, de aumentar a eficácia de um tratamento de câncer, de atrasar e/ou prevenir o desenvolvimento de câncer, de tratamento de um indivíduo, de aumentar a sensibilidade a um agente de terapia, de prolongar o período de uma sensibilidade de agente de terapia e de prolongar a duração da resposta a uma terapia?

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]